Cefepime Injection 1 gram (Meropenem Trihydrate)

Adult administration

As Meropenem hydrate, administer 0.5 to 1 g (potency) daily divided into 2 to 3 doses via intravenous infusion over at least 30 minutes. For suspected infections in patients with pathogenic pneumonia, peritonitis, and neutropenia, administer 1 g (potency) via intravenous infusion every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) via intravenous infusion every 8 hours.

Child administration

For bacterial meningitis in children over 3 months of age, administer a continuous intravenous infusion of 40 mg per kg of body weight every 8 hours over 30 minutes, depending on the sensitivity of the pathogen and the patient's condition, and the type of infection. Additionally

This medication should not be used in patients who have experienced a severe allergic reaction or shock to this medication or to similar components in the past. Patients taking valproate sodium should not use this medication as it may reduce the efficacy of valproate and result in the recurrence of seizures. Patients with bronchial asthma or a history of allergies, those with renal or liver problems, those with a history of epilepsy, and infants under three months old should use this medication with caution. During treatment with this drug, serious side effects such as shock, severe skin rashes, blood disorders, liver or kidney dysfunction, severe colitis, and seizures may occur, so symptoms should be closely monitored. Particularly, if symptoms such as dizziness, rash, shortness of breath, abdominal pain, diarrhea, muscle pain, or inflammation at the injection site occur after administration, medical personnel should be notified immediately. This medication should be used only for the necessary duration after confirming its effectiveness against the causative pathogen to prevent the emergence of resistant bacteria. Also, prior to administering this medication, it must be confirmed if there is any history of allergy to beta-lactam antibiotics such as penicillin or cephalosporins. This medication may interact with certain drugs; therefore, it is essential to inform healthcare providers if other medications are being taken, especially when used alongside valproate, antiepileptic medications, contraceptives, and warfarin. Pregnant women or those at risk of pregnancy should only use this medication when the benefits outweigh the risks, and nursing mothers should avoid breastfeeding while this medication is being used. Elderly patients may experience side effects more readily due to weakened bodily functions, thus they should use this medication carefully with adjusted dosages and intervals. This medication is administered only intravenously and should be used as soon as it is dissolved, adhering to the specified time for storage. Finally, any unusual symptoms or discomfort that arise during the use of this medication should be reported to healthcare providers immediately to receive appropriate care.

Serious side effects

Shock, anaphylaxis, respiratory distress, wheezing, severe skin reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, erythema multiforme, acute generalized exanthematous pustulosis, fulminant hepatitis, liver failure, jaundice, acute renal failure, severe diarrhea, pseudomembranous colitis, seizures, altered consciousness, asthma, pleural effusion, interstitial pneumonia, pulmonary edema, PIE syndrome, heart failure, cardiac arrest, myocardial infarction, pulmonary embolism, syncope,

Mild side effects

• Urticaria
• rash
• warmth
• erythema
• itching
• fever
• redness
• generalized flushing
• angioedema
• panocytopenia

This medication should be stored in a tightly sealed container at room temperature between 1 degree Celsius and 30 degrees Celsius. Proper storage is essential to maintain the drug's efficacy and safety.

Appearance

Vial filled with crystalline powder, white to pale yellow in color

Package unit

10 vials